Posted by admin on Aug 18th, 2022
Alphatec (NASDAQ:ATEC – Get Rating) and NEXGEL (NASDAQ:NXGL – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.
This table compares Alphatec and NEXGEL’s net margins, return on equity and return on assets.
This is a breakdown of recent ratings and price targets for Alphatec and NEXGEL, as reported by MarketBeat.com.
Alphatec currently has a consensus target price of $15.08, indicating a potential upside of 68.91%. NEXGEL has a consensus target price of $5.00, indicating a potential upside of 179.33%. Given NEXGEL’s stronger consensus rating and higher probable upside, analysts clearly believe NEXGEL is more favorable than Alphatec.
53.5% of Alphatec shares are held by institutional investors. Comparatively, 2.0% of NEXGEL shares are held by institutional investors. 33.9% of Alphatec shares are held by insiders. Comparatively, 25.2% of NEXGEL shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This table compares Alphatec and NEXGEL’s top-line revenue, earnings per share and valuation.
NEXGEL has lower revenue, but higher earnings than Alphatec.
NEXGEL beats Alphatec on 6 of the 10 factors compared between the two stocks.
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier, as well as EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States. The company was founded in 1990 and is headquartered in Carlsbad, California.
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was founded in 1997 and is based in Langhorne, Pennsylvania.
Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.
Stock Traders Buy High Volume of Call Options on nVent Electric (NYSE:NVT)
Comparing Valens Semiconductor (VLN) & The Competition